Media headlines about DBV Technologies (NASDAQ:DBVT) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. DBV Technologies earned a daily sentiment score of 0.13 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 45.5197009451612 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the media stories that may have effected Accern Sentiment Analysis’s rankings:
A number of research analysts have issued reports on DBVT shares. BidaskClub raised shares of DBV Technologies from a “hold” rating to a “buy” rating in a research report on Thursday, January 11th. Zacks Investment Research downgraded shares of DBV Technologies from a “hold” rating to a “sell” rating in a research report on Monday, December 25th. JMP Securities began coverage on shares of DBV Technologies in a research report on Friday, November 17th. They issued an “outperform” rating on the stock. Finally, Citigroup set a $57.00 target price on shares of DBV Technologies and gave the stock a “buy” rating in a research report on Wednesday, February 14th. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $49.63.
Shares of DBV Technologies (NASDAQ:DBVT) opened at $22.36 on Wednesday. DBV Technologies has a 1 year low of $20.08 and a 1 year high of $50.57.
DBV Technologies Company Profile
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.